Application of neuropsychological criteria to classify mild cognitive impairment in the active study

Kelsey R Thomas1, Sarah E Cook2, Mark W Bondi1

  • 1Veterans Affairs San Diego Healthcare System.

Neuropsychology
|November 16, 2020
PubMed

Insights

Comprehensive neuropsychological (NP) criteria accurately identify mild cognitive impairment (MCI) and predict functional decline. This study applied NP criteria in the ACTIVE trial, finding MCI predicts future loss of independence, especially amnestic MCI.

Area of Science:

  • Gerontology
  • Neuropsychology
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) diagnosis impacts dementia risk prediction.
  • Conventional MCI criteria have limitations in accuracy and predictive power.
  • Neuropsychological (NP) criteria offer a more comprehensive approach to MCI classification.

Purpose of the Study:

  • To implement and evaluate actuarial NP criteria for MCI classification within the ACTIVE study.
  • To examine MCI prevalence, reversion rates, and baseline characteristics by MCI subtype.
  • To assess the longitudinal association between MCI subtypes and functional independence.

Main Methods:

  • Classified 2,755 ACTIVE study participants as cognitively normal (CN) or MCI using NP criteria.
  • Estimated MCI prevalence and reversion rates.
  • Utilized mixed-effects models to analyze MCI subtype associations with 10-year trajectories of self-reported independence and instrumental activities of daily living (IADLs).

Main Results:

  • An estimated 18.8% of participants met MCI criteria, with a 19.2% reversion rate to CN status.
  • The multidomain-amnestic MCI group exhibited the most significant cognitive impairment and IADL difficulties at baseline.
  • MCI classification predicted faster IADL decline over 10 years, with multidomain-amnestic MCI showing the steepest decline.

Conclusions:

  • NP criteria yield MCI prevalence and reversion rates consistent with community-dwelling samples.
  • MCI classification, particularly amnestic MCI, is predictive of future declines in functional independence.
  • Further research will explore the relationship between MCI subtypes and intervention-related factors in the ACTIVE cohort.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.3K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
379
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
583